Does LAPATINIB Cause Second primary malignancy? 27 Reports in FDA Database
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 27 reports of Second primary malignancy have been filed in association with LAPATINIB. This represents 1.4% of all adverse event reports for LAPATINIB.
27
Reports of Second primary malignancy with LAPATINIB
1.4%
of all LAPATINIB reports
22
Deaths
0
Hospitalizations
How Dangerous Is Second primary malignancy From LAPATINIB?
Of the 27 reports, 22 (81.5%) resulted in death, and 2 (7.4%) were considered life-threatening.
Is Second primary malignancy Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for LAPATINIB. However, 27 reports have been filed with the FAERS database.
What Other Side Effects Does LAPATINIB Cause?
Diarrhoea (382)
Disease progression (227)
Palmar-plantar erythrodysaesthesia syndrome (182)
Malignant neoplasm progression (173)
Nausea (161)
Metastases to central nervous system (160)
Neutropenia (160)
Vomiting (155)
Asthenia (148)
Fatigue (139)
What Other Drugs Cause Second primary malignancy?
CYCLOPHOSPHAMIDE (1,247)
DOXORUBICIN (1,151)
VINCRISTINE (908)
IMATINIB (763)
PALBOCICLIB (658)
RITUXIMAB (646)
RUXOLITINIB (611)
ETOPOSIDE (573)
PREDNISONE (517)
OCTREOTIDE (496)
Which LAPATINIB Alternatives Have Lower Second primary malignancy Risk?
LAPATINIB vs LAPATINIB DITOSYLATE
LAPATINIB vs LAPINE T-LYMPHOCYTE IMMUNE GLOBULIN
LAPATINIB vs LARONIDASE
LAPATINIB vs LAROTRECTINIB
LAPATINIB vs LASILIX